Abstract:Aβ 1–42 is the proteolytic cleavage product of cleavage of the amyloid precursor protein by β- and γ-secretases. The aggregation of Aβ 1–42 plays a causative role in the development of Alzheimer’s disease. To lock Aβ 1–42 in a homogenous state, we embedded the Aβ 1–42 sequence in an unstructured region of Bcl-x L . Both the N-terminus and the C-terminus of Aβ 1–42 were constrained in the disordered region, whereas the conjunction did not introduce any folding to Aβ 1–42 but maintained the sequence as a monomer in solution. With Bcl-x L -Aβ 42 , we developed an enzyme-linked immunosorbent assay to compare the affinity of compounds for monomeric Aβ 1–42 . Bcl-x L -Aβ 42 was coated on a microplate and this was followed by incubation with different concentrations of compounds. Compounds binding to Leu17-Val24 of Aβ 1–42 inhibited the interaction between Bcl-x L -Aβ 42 and antibody 4G8. The method can not only reproduce the activities of the reported Aβ 1–42 inhibitors such as dopamine, tannin, and morin but can also differentiate decoy compounds that do not bind to Aβ 1–42 . Remarkably, using this method, we discovered a new inhibitor that binds to monomeric Aβ 1–42 and inhibits Aβ 1–42 fibril formation. As the structure of Bcl-x L -Aβ 42 monomer is stable in solution, the assay could be adapted for high-throughput screening with a series of antibodies that bind the different epitopes of Aβ 1–42 . In addition, the monomeric form of the Aβ 1–42 sequence in Bcl-x L -Aβ 42 would also facilitate the identification of Aβ 1–42 binding partners by coimmunoprecipitation, cocrystallization, surface plasmon resonance technology, or the assay as described here. Figure Schematic diagram of an enzyme-linked immunosorbent assay to compare the affinity of chemical compounds for β-amyloid peptide in monomer

A Rapid Pipeline to Identify Small Molecule Inhibitors of Amyloid Aggregation

A rapid in vivo pipeline to identify small molecule inhibitors of amyloid aggregation

Inhibitor discovery targeting the intermediate structure of β-amyloid peptide on the conformational transition pathway: Implications in the aggregation mechanism of β-amyloid peptide

Inhibitor discovery targeting the intermediate structure of beta-amyloid peptide on the conformational transition pathway: implications in the aggregation mechanism of beta-amyloid peptide.

Α-Helical Motif As Inhibitors of Toxic Amyloid-β Oligomer Generation Via Highly Specific Recognition of Amyloid Surface

Screening Carbon Nano Materials for Preventing Amyloid Protein Aggregation by Adopting a Facile Method

An aggregation inhibitor specific to oligomeric intermediates of Aβ42 derived from phage display libraries of stable, small proteins

Diphenylalanine as a Reductionist Model for the Mechanistic Characterization of β-Amyloid Modulators

Structure-Based Peptide Inhibitor Design of Amyloid-β Aggregation

An enzyme-linked immunosorbent assay to compare the affinity of chemical compounds for β-amyloid peptide as a monomer

Targeting the Amyloid-β Fibril Surface with a Constrained Helical Peptide Inhibitor.

Accelerating Protein Aggregation and Amyloid Fibrillation for Rapid Inhibitor Screening

A Chemical Perspective to the Anti-Amyloid Action of Compounds and a Nanoparticle Based Assay for Screening Amyloid Inhibitors

Rationally Designed Peptoid Inhibitors of Amyloid‐β Oligomerization

Amyloid binding and beyond: a new approach for Alzheimer's disease drug discovery targeting Aβo-PrPC binding and downstream pathways

Molecular engineering of a theranostic molecule that detects Aβ plaques, inhibits Iowa and Dutch mutation Aβ self-aggregation and promotes lysosomal biogenesis for Alzheimer's disease

Macromolecular and small-molecule modulation of intracellular Aβ42 aggregation and associated toxicity.

Repurposing Anidulafungin for Alzheimer's Disease via Fragment-Based Drug Discovery

Identification of Inhibitors for Amyloid-beta in Alzheimer's Disease and Cerebral Amyloid Angiopathy

An efficient biochemical method for characterizing and classifying potentially amyloidogenic and therapeutic peptides

Design of amyloidogenic peptide traps